Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.